title: Safety of etanercept therapy in rheumatoid patients undergoing surgery: preliminary report.
abstract: This is a preliminary report on a case-series of rheumatoid patients that underwent various kinds of elective surgery but did not withdraw etanercept therapy in spite of physician advise. Elective surgery consisted of right knee surgical prosthesis, bilateral cataract, bilateral hallux valgus, right hip prosthesis, bladder stone by cystoscopy and left inguinal hernia. All the patients had a regular healing rate. During follow-up (6-12 months) no one of these patients were suffering from infective complications after surgery. According to same recent literature results, our data suggest that it is the time to value rheumatoid patient preferences through a correct information about cost-benefit of this treatment to establish together with patients if etanercept therapy has to be discontinued before and after elective surgery. Finally, we think that adverse drug reaction surveillance has to be boosted, and editors of leading scientific journal should publish more papers on case-series about drug safety and tolerability in particular conditions.
authors.affiliation: Biomedical Department of Internal Medicine, University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy. s.corrao@tiscali.it
authors.forename: Salvatore
authors.initials: S
authors.lastname: Corrao
authors.forename: Giovanni
authors.initials: G
authors.lastname: Pistone
authors.forename: Sabrina
authors.initials: S
authors.lastname: Arnone
authors.forename: Luigi
authors.initials: L
authors.lastname: Calvo
authors.forename: Rosario
authors.initials: R
authors.lastname: Scaglione
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Licata
mesh_terms: D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000075202:Contraindications; D017558:Elective Surgical Procedures / Q000009:adverse effects*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011183:Postoperative Complications / Q000139:chemically induced / Q000276:immunology; D011184:Postoperative Period; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014945:Wound Healing
chemical_list: D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept